Neutral tumor evolution?

No abstract available

Methods and practice of detecting selection in human cancers

Cancer development and progression is an evolutionary process, understanding these evolutionary dynamics is important for treatment and diagnosis as how a cancer evolves determines its future prognosis. This thesis focuses on elucidating selective evolutionary pressures in cancers and somatic tissues using population genetics models and cancer genomics data. First a model for the expected diversity in the absence of selection was developed. This neutral model of evolution predicts that under neutrality the frequency of subclonal mutations is expected to follow a power law distribution. Surprisingly more than 30% of cancer across multiple cohorts fitted this model. The next part of the thesis develops models to explore the effects of selection given these should be observable as deviations from the neutral prediction. For this I developed two approaches. The first approach investigated selection at the level of individual samples and showed that a characteristic pattern of clusters of mutations is observed in deep sequencing experiments. Using a mathematical model, information encoded within these clusters can be used to measure the relative fitness of subclones and the time they emerge during tumour evolution. With this I observed strikingly high fitness advantages for subclones of above 20%. The second approach enables measuring recurrent patterns of selection in cohorts of sequenced cancers using dN/dS, the ratio of non-synonymous to synonymous mutations, a method originally developed for molecular species evolution. This approach demonstrates how selection coefficients can be extracted by combining measurements of dN/dS with the size of mutational lineages. With this approach selection coefficients were again observed to be strikingly high. Finally I looked at population dynamics in normal colonic tissue given that many mutations accumulate in physiologically normal tissue. I found that the current view of stem cell dynamics was unable to explain sequencing data from individual colonic crypts. Some new models were proposed that introduce a longer time scale evolution that suppresses the accumulation of mutations which appear consistent with the data

Discovering Subclones and Their Driver Genes in Tumors Sequenced at Standard Depths

abstract: Understanding intratumor heterogeneity and their driver genes is critical to designing personalized treatments and improving clinical outcomes of cancers. Such investigations require accurate delineation of the subclonal composition of a tumor, which to date can only be reliably inferred from deep-sequencing data (>300x depth). The resulting algorithm from the work presented here, incorporates an adaptive error model into statistical decomposition of mixed populations, which corrects the mean-variance dependency of sequencing data at the subclonal level and enables accurate subclonal discovery in tumors sequenced at standard depths (30-50x). Tested on extensive computer simulations and real-world data, this new method, named model-based adaptive grouping of subclones (MAGOS), consistently outperforms existing methods on minimum sequencing depth, decomposition accuracy and computation efficiency. MAGOS supports subclone analysis using single nucleotide variants and copy number variants from one or more samples of an individual tumor. GUST algorithm, on the other hand is a novel method in detecting the cancer type specific driver genes. Combination of MAGOS and GUST results can provide insights into cancer progression. Applications of MAGOS and GUST to whole-exome sequencing data of 33 different cancer types’ samples discovered a significant association between subclonal diversity and their drivers and patient overall survival.Dissertation/ThesisDoctoral Dissertation Biomedical Informatics 201

Computational Cancer Biology: An Evolutionary Perspective

ISSN:1553-734XISSN:1553-735

Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer

The extent of heterogeneity among driver gene mutations present in naturally occurring metastases - that is, treatment-naive metastatic disease - is largely unknown. To address this issue, we carried out 60× whole-genome sequencing of 26 metastases from four patients with pancreatic cancer. We found that identical mutations in known driver genes were present in every metastatic lesion for each patient studied. Passenger gene mutations, which do not have known or predicted functional consequences, accounted for all intratumoral heterogeneity. Even with respect to these passenger mutations, our analysis suggests that the genetic similarity among the founding cells of metastases was higher than that expected for any two cells randomly taken from a normal tissue. The uniformity of known driver gene mutations among metastases in the same patient has critical and encouraging implications for the success of future targeted therapies in advanced-stage disease

Genomic Evolution of Glioblastoma

Understanding how tumors evolve and drive uncontrolled cellular growth may lead to better prognosis and therapy for individuals suffering from cancer. A key to understanding the paths of progression are to develop computational and experimental methods to dissect clonal heterogeneity and statistically model evolutionary routes. This thesis contains results from analysis of genomic data using computational methods that integrate diverse next generation sequencing data and evolutionary concepts to model tumor evolution and delineate likely routes of genomic alterations. First, I introduce some background and present studies into how tumor genomic sequencing tells us about tumor evolution. This will encompass some of the principles and practices related to tumor heterogeneity within the field of computional biology. Second, I will present a study of longitudinal sampling in Glioblastoma (GBM) in cohort of 114 individuals pre- and post-treatment. We will see how genomic alterations were dissected to uncover a diverse and largely unexpected landscape of recurrence. This details major observations that the recurrent tumor is not likely seeded by the primary lesion. Second, to dissect heterogeneity from clonal evolution, multiple biopsies will be added to extend our longitudinal GBM cohort. This new data will introduce analyses to explicate inter and intra-tumor heterogeneity of GBM. Specifically, we identify a metric of intratumor heterogeneity able to identify multisector biopsies and propose a model of tumor growth in multiple GBM. These results will relate to clinical outcome and are in agreement with previously established hypotheses in truncal mutation targeting. Fourth, I will introduce new models of clonal growth applicable to 2 patient biopsies and then fit these to our GBM cohort. Simulations are used to verify models and a brief proof is presented

Inference Of Natural Selection In Human Populations And Cancers: Testing, Extending, And Complementing Dn/ds-Like Approaches

Heritable traits tend to rise or fall in prevalence over time in accordance with their effect on survival and reproduction; this is the law of natural selection, the driving force behind speciation. Natural selection is both a consequence and (in cancer) a cause of disease. The new abundance of sequencing data has spurred the development of computational techniques to infer the strength of selection across a genome. One technique, dN/dS, compares mutation rates at mutation-tolerant synonymous sites with those at nonsynonymous sites to infer selection. This dissertation tests, extends, and complements dN/dS for inferring selection from sequencing data. First, I test whether the genomic community’s understanding of mutational processes is sufficient to use synonymous mutations to set expectations for nonsynonymous mutations. Second, I extend a dN/dS-like approach to the noncoding genome, where dN/dS is otherwise undefined, using conservation data among mammals. Third, I use evolutionary theory to co-develop a new technique for inferring selection within an individual patient’s tumor. Overall, this work advances our ability to infer selection pressure, prioritize disease-related genomic elements, and ultimately identify new therapeutic targets for patients suffering from a broad range of genetically-influenced diseases